Roche's phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
I'm PortAI, I can summarize articles.
Basel, 18 October 2025 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today positive results from the phase III evERA Breast Cancer study. Data showed giredestrant in combination with everolimus significantly reduced the risk of disease progression or death ( progression-free survival.
Source: GlobeNewswire The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments